In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel vaccine his research group is developing to combat prostate cancer. Dr Gulley outlines how prostvac works and describes the three arms of the PROSPECT Phase III trial (NCT01322490), before speaking about the preliminary results, which at first did not seem very conclusive, but, upon further analysis, did show a low level of efficacy. Dr Gulley then concludes his interview by referring to two patients who showed an incredible response to the drug, and what this means for its future. This interview was recorded at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL.